AKT1 and breast carcinoma: Sun et al. [37] documented that SC79 upregulated the expression of p-AKT and suppressed regorafenib-induced apoptosis, as well as restored regorafenib-mediated inhibition of proliferation in breast cancer cells, which further implicated that regorafenib exerted functions on tumor cells by deactivating the PI3K/AKT pathway.